Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study)

Abstract

The present observational study aimed to evaluate the clinical effectiveness of vildagliptin with metformin in Korean patients with type 2 diabetes mellitus (T2DM). Data were pooled from the vildagliptin postmarketing survey (PMS), the vildagliptin/metformin fixed drug combination (DC) PMS, and a retrospective observational study of vildagliptin/metformin (fixed DC or free DC). The effectiveness endpoint was the proportion of patients who achieved a glycemic target (HbA1c) of ≤7.0% at 24 weeks. In total, 4303 patients were included in the analysis; of these, 2087 patients were eligible. The mean patient age was 56.99 ± 11.25 years. Overall, 58.94% patients achieved an HbA1c target of ≤7.0% at 24 weeks. The glycemic target achievement rate was significantly greater in patients with baseline HbA1c < 7.5% versus ≥7.5% (84.64% versus 43.97%), receiving care at the hospital versus clinic (67.95% versus 52.33%), and receiving vildagliptin/metformin fixed DC versus free DC (70.69% versus 55.42%). Multivariate logistic regression analysis indicated that disease duration (P < 0.0001), baseline HbA1c (P < 0.0001), and DC type (P = 0.0103) had significant effects on drug effectiveness. Vildagliptin plus metformin appeared as an effective treatment option for patients with T2DM in clinical practice settings in Korea.

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study

“…Interestingly, patients switched to the SPC of vildagliptin and metformin showed no difference in mean HbA1c at study end compared to those who remained on vildagliptin and metformin, but the switched patients showed greater reductions in mean FPG and higher HbA1c and FPG goal achievement rates despite similar patient-reported adherence rates. These results confirm the previous findings of the VICTORY study showing a higher proportion of patients achieving the glycemic goal when treated with the SPC of vildaliptin and metformin as compared to the free regimen [ 30 ]. In short, both vildagliptin and the SPC of vildagliptin and metformin are effective agents in the management of diabetes across the age spectrum, while the SPC of vildagliptin/metformin can provide a more convenient alternative that ensures at least comparable effectiveness and safety.…”

“…demonstrating that higher baseline HbA1c levels are associated with greater reductions in HbA1c levels, irrespective of class or mode of action of the drug [ 26 ]. Also, the HbA1c reduction seen in the present study confirms results from other observational studies with vildagliptin showing reductions in HbA1c level of between 0.8 and 1.19% for baseline HbA1c levels ranging from 7.8 to 8.2% [ 27 – 30 ]. A post-hoc analysis of the Belgian patients included in the EDGE study, a 1-year observational study with vildagliptin in T2DM patients with a baseline HbA1C of 8.4%, revealed a decrease of 0.81% in HbA1c, a value comparable to that achieved in the present study [ 31 ].…”

“…reported slightly higher goal achievement rates of 54% in their 52-week investigation [ 16 ], but this can be explained by the lower HbA1c baseline value of 7.3% as compared to 8.2% in the G-FORCE study. Compared to other real-world observational studies, we achieved similar goal rates in our study: for example, in the VILDA [ 30 ] and VICTORY [ 30 ] studies, 44.9 and 58.9% of the patients, respectively, achieved the glycemic target after 6 months of treatment with vildagliptin, starting from an HbA1c baseline of 7.8 and 8%, respectively.…”

Applying Machine Learning Models to Electronic Health Records for Chronic Disease Diagnosis in Kuwait

“…[5]. Diabetes is recognized as a chronic illness with the world's fastest growing rate at the same time [6]. Diabetes affects 415 million people worldwide, accounting for 12% of total medical spending ($673 billion) [6].…”

Design, Development, Formulation, and Evaluation of Gastro retentive Floating Tablet for Anti-diabetic Agent

“…[4] Since 1980, the age-adjusted predominance of diabetes in adults has improved, which has brought about quadrupling of the quantity of influenced adults with diabetes in nations around the world. [5,6] Vildagliptin is a new anti-diabetic drug. It has a place with the dipeptidyl peptidase IV (DPP-4) inhibitors and takes action on the incretin system.…”